REG - Advanced Oncotherapy - Two-Year Collaborative Research Study

Advanced OncotherapyAnnouncement

04/12/2019 07:05

RNS Number : 5681V
Advanced Oncotherapy PLC
04 December 2019
 


The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
 
4 December 2019
 
ADVANCED ONCOTHERAPY PLC
 
("Advanced Oncotherapy" or the "Company")
 
Advanced Oncotherapy plc (AIM: AVO) announces a two-year collaborative research study.
 
Under the agreement, Advanced Oncotherapy plc (AIM:AVO) and Cleveland Clinic, a large academic medical centre in Cleveland, Ohio, USA will commence a two-year study to evaluate the target conformity of proton minibeams in comparison with X-ray stereotactic body radiation therapy ("SBRT") and stereotactic radiosurgery ("SRS").
 
Further explanatory details on the research collaboration, SBRT and SRS are set out below.
 
- ENDS -
 
 



Advanced Oncotherapy plc


www.avoplc.com




Dr. Michael Sinclair, Executive Chairman


Tel: +44 (0) 20 3617 8728




Nicolas Serandour, CEO


















Allenby Capital Limited (Nomad & Broker)








Nick Athanas / Liz Kirchner / Nicholas Chambers


Tel: +44 (0) 20 7601 6100














FTI Consulting (Financial PR & IR)


advancedoncotherapy@fticonsulting.com




Simon Conway / Rob Winder


Tel: +44 (0) 20 3727 1000



 
Notes for Editors
 
About the research collaboration
Innovation in radiotherapy is focused on increasing the efficacy of treatment and improving quality of life for patients through a reduction of side effects or increased long-term survival. The most challenging goal of radiotherapy is ensuring that only the cancerous tissue is targeted, avoiding the irradiation of healthy tissue. The use of a smaller beam means greater accuracy in targeting the desired tissue, which is essential when treating tumours near critical organs, particularly for the edge of the tumours.
 
Focus within proton therapy is on initiatives to generate smaller and more accurate beams. Advanced Oncotherapy's LIGHT has been designed to generate a much smaller beam, a minibeam, than is possible with current proton therapy technology.
 
Proton mini beam radiation therapy ("pMBRT")
Proton minibeam radiation therapy is an approach to radiation therapy that allies the inherent physical advantages of protons with the normal tissue preservation when the tumour is irradiated with sub-millimetric proton beams, i.e., below the current standard size of proton beams.
 
X-ray stereotactic body radiation therapy ("SBRT") and X-ray stereotactic radiosurgery ("SRS")
Stereotactic radiosurgery (SRS) is a non-surgical radiation therapy used to treat functional abnormalities and small tumours of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy. When SRS is used to treat body tumours, it is called stereotactic body radiotherapy (SBRT).
 
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
 
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
 
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRMMMGZLFNGLZM